# Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

> **NCT04421885** · PHASE1 · COMPLETED · sponsor: **Spero Therapeutics** · enrollment: 36 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference
- **DRUG:** Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test

## Key facts

- **NCT ID:** NCT04421885
- **Lead sponsor:** Spero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2020-07-11
- **Final completion:** 2020-07-29
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04421885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04421885, "Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04421885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*